Objectives: Verify the efficacy of the GLP-1 analogue exenatide in patients with type 2 DM assisted in our hospital area.
Material and methods: This study included patients who initiated this therapy in 2008 and 2009. Through 3 months were analyzed the outcomes of weight, HbA1c and the development of adverse effects.
Results: The process included 32 patients, 21 men and 11 women, with ages between 26 and 73 years old (mean age 48.78 years) and mean DM evolution of 6.25 years. Prior to introducing exenatide 35% of them were in treatment with one single type of oral antidiabetic drug, 44% with two oral drugs and 20.6% with three oral drugs. Initial data were weight (109.9±24.1 kg), BMI (38.58±6.4 kg/m2), and HbA1c (8.24±1.8%). During the first month of follow up, the mean weight reduction was 2.6±2.2 kg, reaching in 3 months 6.6±4.9 kg. This difference was statistically significant (P<0.01 Wilcoxon test). HbA1c showed a decrease of 1.6±1.4 points in 3 months (P<0.01 Wilcoxon test). 18.7% of patients had mild adverse effects (nausea, dyspepsia) at the beginning of therapy, while in two of them had to be retired because of emesis.
Conclusions: In general exenatide showed an important improvement of weight reduction and glycemic control, being in most cases well tolerated by our obese type 2 DM patients. Nevertheless, would be necessary a long-term study to confirm these hopeful results.
Prague, Czech Republic
24 - 28 Apr 2010
European Society of Endocrinology